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To evaluate the effects of Bifidobacterium animalis subsp. lactis HN019 (HN019) on clinical
periodontal parameters (plaque accumulation and gingival bleeding), on immunocompe-
tence of gingival tissues [expression of beta-defensin (BD)-3, toll-like receptor 4 (TLR4),
cluster of differentiation(CD)-57 and CD-4], and on immunological properties of saliva
(IgA levels) in non-surgical periodontal therapy in generalized chronic periodontitis (GCP)
patients. Adhesion to buccal epithelial cells (BEC) and the antimicrobial properties of
HN019 were also investigated.
Materials and methods
Thirty patients were recruited and monitored clinically at baseline (before scaling and root
planing—SRP) and after 30 and 90 days. Patients were randomly assigned to Test (SRP
+Probiotic, n = 15) or Control (SRP+Placebo, n = 15) group. Probiotic lozenges were used
for 30 days. Gingival tissues and saliva were immunologically analyzed. The adhesion of
HN019 with or without Porphyromonas gingivalis in BEC and its antimicrobial properties
were investigated in in vitro assays. Data were statistically analyzed (p<0.05).
Results
Test group presented lower plaque index (30 days) and lower marginal gingival bleeding (90
days) when compared with Control group. Higher BD-3, TLR4 and CD-4 expressions were
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observed in gingival tissues in Test group than in Control group. HN019 reduced the adhe-
sion of P. gingivalis to BEC and showed antimicrobial potential against periodontopathogens.
Conclusion
Immunological and antimicrobial properties of B. lactis HN019 make it a potential probiotic
to be used in non-surgical periodontal therapy of patients with GCP.
Clinical relevance
B. lactis HN019 may be a potential probiotic to improve the effects of non-surgical periodon-
tal therapy.
Name of the registry and registration number (ClinicalTrials.gov): “Effects of probiotic
therapy in the treatment of periodontitis”—NCT03408548.
Introduction
In periodontal diseases, the first triggering mechanism is dental plaque accumulation as a
result of poor oral hygiene [1]. Some studies have suggested that several periodontal pathogens
may colonize supragingival biofilm, which can contribute to subgingival recolonization of
recently treated sites [2–5]. This finding has led to strict professional plaque control (PPC) as
part of the periodontal treatment [6, 7], but with the inconvenience that it is difficult to ensure
that patients return to the dental office frequently for long periods. Maintenance of gingival
health after non-surgical periodontal therapy (NSPT) could prevent the increase of gingival
crevicular fluid and, consequently, the augmentation of proteins that act as a source of nutri-
ents for periodontopathogens [1]. In fact, it has been demonstrated that one promising strat-
egy for the control and treatment of periodontal diseases is the modulation of the host
inflammatory response, since it is evident that some keystone pathogens are attracted by
inflammation. Therefore, the control of inflammation is of paramount importance for manag-
ing the infection [8].
In this context, a possible adjuvant therapy for the prevention of gingival inflammation and
dental plaque accumulation in non-surgical periodontal treatment is the use of probiotics. Pro-
biotics are defined as “live microorganisms which when administered in adequate amounts
confer a health benefit on the host” [9]. Probiotics might play a possible role in oral health by
suppressing and displacing harmful bacteria and indirectly by producing immunomodulatory
effects [10].
A number of in vivo studies have focused on the role of probiotics in the prevention and
treatment of periodontal diseases [11–17]. It has been shown that probiotics are useful in
reducing gingival inflammation [11–15] and plaque accumulation [12, 13], improving peri-
odontal health [11, 16, 17] and reducing proinflammatory cytokines in patients with gingivitis
[14] and periodontitis [18].
To be effective against oral infections, probiotic bacteria need to adhere to the oral mucosa
and to dental tissues as part of the biofilm and compete with the growth of dental pathogens.
In fact, it has been demonstrated that some probiotic bacteria can interfere both quantitative
and qualitatively with the oral biofilm [19–21]. Haukioja et al. 2006 demonstrated a trend for
two Bifidobacterium strains to bind to buccal cells and intestinal mucus [22]. This ability sug-
gests that probiotics might modulate innate and adaptive immune defenses by releasing
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soluble factors which can trigger signaling cascades in epithelial cells [23, 24]. In short, differ-
ent immune components actively kill, inhibit, and agglutinate microbes [lysozyme, defensins,
histatins, immunoglobulin (Ig) A], deprive them of iron (lactoferrin), prevent their adhesion
(IgA, IgG, IgM), or act as opsonins (complement, IgG, IgM) that increase phagocytosis by
immune cells [25].
Bifidobacteria occur naturally in the oral cavity [26] and are among the most predominant
anaerobic bacteria within the intestinal lumen. A body of evidence suggests that bifidobacteria
play a critical role in maintaining the normal balance of the gut microbiota [27], and a number
of probiotic-induced benefits to general health have been proposed. The possible impact on
oral health has been poorly explored.
Kuru et al. (2017) demonstrated that the use of a probiotic yogurt supplemented with B.
animalis could have a positive effect on plaque accumulation and on gingival inflammation
after abstinence from oral hygiene practices [19]. Ricoldi et al. (2017) observed that Bifidobac-
terium animalis subsp. lactis (B. lactis) HN019 increased the expression of anti-inflammatory
cytokines and reduced the expression of proinflammatory cytokines in rats with experimental
periodontitis [28]. Oliveira et al. (2017) verified greater osteoprotegerin and beta-defensins
(BD) expressions in periodontal tissues of rats with experimental periodontitis treated with B.
lactis HN019 when compared with untreated rats [29].
A recent study demonstrated the effects of B. lactis HN019 as an adjunct to non-surgical
therapy in generalized chronic periodontitis (GCP) patients [30]. The patients treated with
probiotic experienced superior results regarding decrease in probing pocket depth and clinical
attachment gain. Furthermore, they demonstrated fewer periodontal pathogens of red and
orange complexes and reduced proinflammatory cytokine levels in gingival crevicular fluid
when compared with patients using placebo.
However, to the authors’ knowledge, no studies have examined the mechanisms of action,
including immunomodulatory properties, of Bifidobacterium-supplemented probiotics in the
oral mucosa of patients with periodontitis. Also, no evaluations regarding the adhesion of B.
lactis HN019 to buccal epithelial cells and B. lactis HN019 antimicrobial activity have been per-
formed. The aim of this study was to evaluate the effects of B. lactis HN019 on clinical peri-
odontal parameters (plaque accumulation and gingival bleeding), on the immunocompetence
of gingival tissues [expression of BD-3, Toll-like receptor 4 (TLR4), cluster of differentiation
(CD)-57 and CD-4], and on immunological properties of saliva (IgA levels) in non-surgical
periodontal therapy in GCP patients. Adhesion to buccal epithelial cells and antimicrobial
properties of B. lactis HN019 were also investigated.
Materials and methods
Patient population
This study includes part of the sample of patients from the study by Invernici et al. [30]. Thirty
patients were selected from the population referred to the Periodontal Clinic at the School of
Dentistry of Ribeirão Preto–University of São Paulo (FORP-USP, Ribeirão Preto, SP, Brazil).
All eligible patients were thoroughly informed of the nature and potential risks and benefits of
their participation in the study and signed an informed consent form. The study protocol was
reviewed and approved by the Research Ethics Committee of FORP-USP (protocol number:
06278012.1.0000.5419), and registered in ClinicalTrials.gov (NCT03408548). The research was
conducted in full accordance with ethical principles, including the World Medical Association
Declaration of Helsinki (version 2008) and additional requirements.
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Inclusion and exclusion criteria
All patients were diagnosed with GCP according to the 1999 classification of the American
Academy of Periodontology [31]. The inclusion criteria were: (1) age over 30 years, (2) 30%
or more of the sites with probing pocket depth (PPD)� 4 mm and clinical attachment level
(CAL)� 4 mm, (4) presence of bleeding on probing (BOP) and a minimum of five teeth with
at least one site with CAL and PPD� 5 mm. All patients had to be in good general health. The
exclusion criteria were: (1) cause-related periodontal therapy in the previous 6 months, (2) sys-
temic and topic antimicrobial therapy (i.g. antibacterials, antifungals, antivirals and antisep-
tics) in the previous 6 months, (3) systemic conditions that could influence the progression of
periodontitis or treatment response (i.e., diabetes mellitus, immunological disorders), (4) preg-
nancy, (5) smoking, (6) extensive prosthetic appliances, (7) need of prophylactic antibiotic
therapy for routine dental procedures, and (8) long-term administration of anti-inflammatory
medications.
Experimental design, allocation concealment, and treatment protocol
According to a random numeric table generated by a computer software, the study coordina-
tor (M.R.M.) allocated each patient to one of the following groups: Control (Scaling and root
planing–SRP + placebo; 15 patients) or Test (SRP + probiotic therapy, 15 patients; Fig 1).
Before the study began, the selected individuals were identified by a numeric code that
Fig 1. Flowchart of the study design.
https://doi.org/10.1371/journal.pone.0238425.g001
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designated the experimental group to which they belonged. The study coordinator (M.R.M.)
broke the code only after conducting the statistical analysis of the experimental data.
The patients received lozenges containing 10 mg of probiotic (Test group) or placebo (Con-
trol group). In the Test group, the lozenges had 109 colony-forming units (CFUs) of B. lactis
HN019 (HOWARU1 Bifido LYO 40 DCU-S, DuPont™ Danisco1 Sweeteners Oy, Kantvik,
Finland). The same pharmacy prepared identical probiotic and placebo lozenges (i.e., same
appearance, taste, and color). Identical plastic bottles containing the probiotic/placebos were
sent to the study coordinator (M.R.M.), who wrote the number code of each patient on each
bottle, according to the therapy to which they were assigned. The coded bottles were given to
the examiner (M.S.M.S.), who was blinded to the content of the lozenges and distributed them
to the patients. In addition, the patients were also blinded to the content of the lozenges and
treatment assignment during the study.
Seven days prior to NSPT, all patients received supragingival plaque control and oral
hygiene instructions. Within 24 h, a specialist in periodontics (M.M.I.), who was blinded to
the experimental groups, performed supragingival and subgingival SRP on all teeth with peri-
odontal involvement, using hand (Gracey Curettes, Hu-Friedy, Chicago, IL, USA) and ultra-
sonic instruments. The patients were instructed (immediately after SRP) to take one lozenge
twice a day (in the morning and before bedtime) for 30 days. They were also instructed not to
take any other probiotic product during the study. The patients received 14 lozenges (placebo
or probiotic) per week. At the end of each week, they had to be seen at the FORP-USP Peri-
odontal Clinic. During their visit, they should bring the packs of lozenges taken during the
week and then they received new lozenges for the subsequent week. At this visit, they were
asked to a questionnaire about their perception of any side effect observed during the con-
sumption of the dietary supplement. One research assistant (P.H.F.S.) conducted these proce-
dures and monitored the patient’s compliance with medication dosage. This assistant was not
examiner or operator in this study.
All patients received immunological and clinical monitoring at baseline, at 30 days, and at
90 days. The evaluations (pre- and post-intervention) were conducted by a single trained and
calibrated examiner (M.S.M.S.), who was blinded to the experimental groups.
Examiner calibration
The Kappa coefficient was used to evaluate examiner calibration regarding the collection of
clinical periodontal parameters for calculation of intra-examiner agreement. Ten patients with
gingivitis (with both bleeding and non-bleeding on probing) not included in the study were
evaluated by the examiner on two separate occasions 48 h apart. Plaque index (PI) and bleed-
ing on marginal probing (BOMP) were measured. Calibration was accepted if measurements
at baseline and at 48 h were consistent in 90% of the measurements.
Clinical measurements
PI was employed to assess the patients’ oral hygiene status. The BOMP value was described 30
s after gently running a periodontal probe (PCPUNC156, Hu-Friedy, Chicago, IL, USA) into
the gingival sulcus. PI and BOMP were scored as absent or present visual plaque and bleeding
(0 or 1, respectively). BOMP and PI were measured at four sites per tooth at baseline, at 30
days, and at 90 days.
Analysis of salivary immunoglobulin A (IgA) levels
At baseline, and also at 30 and 90 days after NSPT, unstimulated saliva was collected in the
morning, after a fasting period of at least 8 h. The patients were instructed not to move the
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tongue, cheeks, or lips during saliva collection. Two minutes after instructions, the patients
spat into the spit sink, thus eliminating initial residues. After that, collection began. Three
3-minute cycles were run, during which the patients kept the saliva in the oral cavity. At the
end of that period, the patients’ residual saliva was collected into a 50-mL polypropylene
Falcon tube (Corning Inc, Corning, NY, USA). The procedure was repeated twice and total
collection time was 9 min. The saliva samples were then transferred into two graduated Eppen-
dorf tubes using a handheld micropipette. Each tube with 1 mL of saliva was stored at -80 ˚C.
IgA levels (mg/dL) were measured in a clinical analysis laboratory by nephelometry at 1.59 to
41.45 mg/dL.
Gingival biopsies and immunohistochemical analysis
At baseline, and also at 30 days after NSPT, samples of gingival tissues (epithelial and connec-
tive tissues) were harvested from a healthy site (PPD < 3 mm) and from a diseased site
(PPD > 5 mm) of each patient. Gingival biopsies were obtained through internal bevel inci-
sions including supracrestal epithelial and connective tissues. Gingival biopsies were embed-
ded in paraffin. Serial sections (4 μm) were performed for visualization of epithelial and
connective tissues. Histological sections were deparaffinized in xylol and hydrated in a
decreasing ethanol series (100˚- 100˚- 100˚- 90˚- 70˚ GL). Antigen retrieval was performed by
immersion of the histological slides in Diva Decloaker buffer (Biocare Medical, Inc., Concord,
CA, USA), in a pressurized chamber (Decloaking Chamber, Biocare Medical, Inc., Concord,
CA, USA) at 95˚ C for 10 min. The samples were rinsed with phosphate-buffered saline (PBS)
0.1M - pH 7.4 between each immunohistochemical step. The histological sections were
immersed in 3% hydrogen peroxide for 1 h and in 1% bovine serum albumin for 12 h to block
endogenous peroxidase activity and nonspecific sites, respectively. Histological slides with
samples from all experimental groups were categorized into four lots. Each lot was incubated
for 24 h using the following primary antibodies: anti-BD-3 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), anti-TLR4 (Santa Cruz Biotechnology, CA, USA), anti-CD-57 (Santa
Cruz Biotechnology, CA, USA) or anti-CD-4 (Santa Cruz Biotechnology, CA, USA). Universal
LSAB™+ Kit/HRP (Dako North America, Inc., Carpinteria CA, USA) was used in the subse-
quent stages. The histological sections were incubated in biotinylated secondary antibody for 2
h and treated with a streptavidin–horseradish peroxidase conjugate for 1 h. 3,3’- diaminoben-
zidine tetrahydrochloride hydrate (Liquid DAB+, Dako North America, Inc., Carpinteria CA,
USA) was used as chromogen, and the histological sections were counterstained with Harris
hematoxylin. As negative control, the specimens were subjected to the procedures described
earlier, without primary antibodies.
Histological sections were analyzed semiquantitatively by a researcher who was blinded to
the experimental groups. The immunolabeled areas were standardized using 250x magnifica-
tion in a 400 μm x 600 μm area at the center of the histological section. The long axis of this
rectangle was perpendicular to an imaginary line at the interface between the epithelial and
connective tissues. The rectangle was positioned in such a way that its upper half contained
predominantly epithelial tissue, whereas its lower half contained predominantly connective tis-
sue. Immunolabeling was defined as a brownish precipitate in cells and/or in the extracellular
matrix captured by a digital camera coupled to a light microscope and later saved in a com-
puter file. Immunolabeling scores were used as follows: 0 –no immunolabeling (no immunore-
activity in the area); score 1 –extremely low immunoreactivity (around 1⁄5 of the area was
immunoreactive); score 2 –low immunoreactivity (around 2⁄5 of the area were immunoreac-
tive); score 3 –moderate immunoreactivity (around 3⁄5 of the area were immunoreactive);
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score 4 –high immunoreactivity (around 4⁄5 of the area were immunoreactive); score 5 –
extremely high immunoreactivity (almost the whole area was immunoreactive).
In vitro assay of the adhesion of B. lactis HN019 and Porphyromonas
gingivalis to buccal epithelial cells (BEC)
The assay was performed as previously described [22], with some modifications as follows:
BEC were collected from one healthy male volunteer. Cells were washed and suspended in
buffered KCl to obtain an optical density (OD)600 of 0.500. Bacterial suspensions were made
from overnight cultures in buffered KCl to obtain an OD600 of 0.1 [= 2 x 107 colony forming
units (CFU)/mL]. Equal amounts of BEC and bacterial suspensions were incubated for 60
min. Control cells were treated with buffer only. After washing, the cells with adherent bacteria
were stained with crystal violet and safranin solutions. All bacteria (indigenous bacteria, B.
lactis HN019, and P. gingivalis—ATCC 33277) adhered to BEC were counted under a light
microscope. Thirty cells were counted from each sample. All bacterial strains were tested in
parallel and the experiments were repeated twice.
In vitro analysis of the antimicrobial activity of B. lactis HN019
The in vitro antimicrobial activity of B. lactis HN019 was assessed against the following period-
ontopathogens using the agar diffusion method, as described by Zhu et al. [32]: P. gingivalis
(W83), Prevotella intermedia (ATCC 25611), Fusobacterium nucleatum (ATCC 25586), and
Aggregatibacter actinomycetemcomitans (ATCC 33393). For that purpose, 200-μL aliquots (109
CFU/mL) of B. lactis HN019, previously grown on MRSA (Difco Laboratories, Detroit, MI,
USA), were inoculated into 15-mm wells in Tryptic soy agar—TSA (Difco), supplemented
with 5 μg/mL of hemin, 1 μg/mL of menadione, and 5% of defibrinated sheep blood, previ-
ously seeded (1.5 x 108 CFU/mL) with indicator microorganisms. After pre-incubation for 30
min at room temperature, TSA plates were incubated at 37˚ C for 72 h under anaerobic (BD
GasPak™ EZ container systems, Becton, Dickinson and Company, Franklin Lakes, NJ, USA)
(P. gingivalis, P. intermedia, and F. nucleatum) or microaerophilic (A. actinomycetemcomitans)
conditions. Thereafter, the diameter (mm) of inhibition halos was measured using a digital cal-
iper. Each indicator strain was tested three times in duplicate.
The means and standard deviations of the zones of inhibition observed in the sensitivity of
different periodontopathogens to B. lactis HN019 were calculated.
Statistical analysis
Each variable was computed per participant and then averaged across patients in both groups.
The significance level was set at 5%.
The within-group and between-group differences for i) PI; ii) BOMP; and iii) IgA levels
were assessed by repeated-measures analysis of variance (ANOVA) followed by Bonferroni
post-hoc test and by Student’s t test, respectively.
The relative frequencies of the scores were calculated for the analysis of immunohistochem-
ical data on BD-3, TLR4, CD-57 and CD-4 immunolabeling, at baseline and at 30 days for
each experimental group, considering healthy and unhealthy sites separately. Significant differ-
ences between groups were determined by the Kruskal-Wallis test, followed by Dunn’s post-
hoc test.
The between-group and within-group differences for adhesion of the strains to BEC were
evaluated by the Kruskal-Wallis test, followed by Dunn’s post-hoc test.
PLOS ONE Bifidobacterium animalis HN019: A potential non-surgical treatment for periodontitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0238425 September 22, 2020 7 / 20
Results
This study started in December 2015 and ended in August 2016. The sample was comprised of
15 patients in the control group (7 female and 8 male) with mean age ± standard deviation
(SD) of 47.67±9.49 years and 15 patients in the test group (10 female and 5 male) with mean
age ± SD of 47.60±9.97 years. The means of teeth in the mouth ± SD were 24.53 ± 2.97 and
22.86 ± 2.85 in Control and Test groups, respectively. There were no statistically significant
differences between these variables. Postoperative healing was uneventful in all cases. No
adverse effects of probiotic therapy were observed.
Clinical monitoring
Table 1 shows mean percentage rates for BOMP and PI. Test group presented lower BOMP at
90 days and lower PI at 30 days when compared to Control group (p<0.05).
Analysis of salivary IgA levels
IgA levels are shown in Fig 2A. No significant changes were observed in IgA levels at 30 and
90 days, compared to baseline, for Test and Control groups (p>0.05). Fig 2B shows mean IgA
ratios (changes in IgA levels in relation to baseline values) at 30 and 90 days. There were no
significant differences between Test and Control groups at 30 and 90 days (p>0.05).
Gingival biopsies and immunohistochemical analysis
The relative frequencies of scores of healthy and diseased sites in Control and Test groups
before and after probiotic therapy are shown in Figs 3 and 4.
The immunohistochemical technique was highly specific for the detection of BD-3 (Fig
5A–5H), TLR4 (Fig 5I–5P), CD-57 (Fig 6A–6H) and CD-4 (Fig 6I–6P). No immunoreactivity
was observed in the negative controls of immunohistochemical reactions. Immunolabeling
stains were defined as dark brown and were circumscribed to cytoplasms and, to a lesser
extent, to extracellular matrices. Immunolabeling of BD-3 was predominantly present in kera-
tinocytes of epithelial tissue and in fibroblasts of connective tissue. Immunolabeling of TLR4
was predominantly present in cells of connective tissue. Immunolabeling of CD-4 and CD-57
was present mainly in inflammatory and macrophage-like cells.
Only the healthy sites of patients treated with probiotics exhibited significantly higher BD-3
and TLR4 immunoreactivity (Fig 3) at 30 days when compared to baseline (p<0.05). At dis-
eased sites, there was significantly higher BD-3 and TLR4 immunoreactivity in both groups at
Table 1. Mean % (± SD) of BOMP and PI at baseline, 30 days and 90 days.
Variables Time point Treatment groups Intergroup Comparison
Test Control Student’s t test
p value
BOMP Baseline 9.17 ± 7.71ª 14.07 ± 7.99a 0.0987
30 days 4.85 ± 5.2b 9.38 ± 8.67b 0.0938
90 days 5.92 ± 6.12a 12.10 ± 8.19a 0.0267
PI Baseline 18.71 ± 12.14ª 22.50 ± 8.54ª 0.2594
30 days 9.58 ± 5.75b 15.33 ± 9.47b 0.0420
90 days 18.27 ± 17.11a 22.66 ± 9.99a 0.2513
BOMP = bleeding on marginal probing; PI = plaque index; SD = standard deviation; Different letters represent significant differences between time points within the
same group (repeated measures ANOVA, Bonferroni post hoc test, p<0.05).
https://doi.org/10.1371/journal.pone.0238425.t001
PLOS ONE Bifidobacterium animalis HN019: A potential non-surgical treatment for periodontitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0238425 September 22, 2020 8 / 20
30 days when compared to baseline (p<0.05) (Fig 3). The Test group exhibited significantly
higher BD-3 and TLR4 expressions on diseased sites at 30 days when compared to Control
group (p<0.05) (Fig 3). In CD-57 analysis, there were no significant differences in intra-
groups or inter-groups comparisons in healthy or diseased sites (Fig 4). No inter or intra-
Fig 2. IgA levels (A) of Test and Control groups at baseline and at 30 and 90 postoperative days. Mean changes in IgA
levels relative to baseline values obtained for the Test and Control groups are shown in (B). Ratio of IgA
levels = changes in IgA levels in relation to baseline values. n.s� No significant changes were observed in IgA levels at
both 30 and 90 days, compared to baseline, for Test and Control groups. n.s�� No significant differences between Test
and Control groups at both 30 and 90 days.
https://doi.org/10.1371/journal.pone.0238425.g002
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groups differences in the expression of CD-4 in healthy sites were observed (Fig 4). Consider-
ing diseased sites, only Test group showed a significantly greater immunoreactivity pattern of
CD-4 at 30 days when compared with baseline (p<0.05) (Fig 4). At 30 days, CD-4 immunore-
activity pattern in diseased sites of Test group was also greater (p<0.05) than that of the Con-
trol group (Fig 4).
In vitro assay of the adhesion of B. lactis HN019 and P. gingivalis to BEC
A background of approximately 13 indigenous bacteria/cells were attached to washed and
untreated BEC. Table 2 shows the mean adhesion of B. lactis HN019 and P. gingivalis to BEC
alone and combined. There was a lower mean adhesion of P. gingivalis combined with B. lactis
HN019 when compared to the mean adhesion of P. gingivalis alone (p<0.05). Similarly, the
adhesion of B. lactis HN019 was influenced by the presence of P. gingivalis (Fig 7).
Fig 3. Relative frequency values for BD-3 and TLR4 immunolabeling scores in Test and Control groups at healthy and diseased sites at baseline
and at 30 postoperative days, as well as within-group and between-group comparison results. �Significant difference (Kruskal-Wallis, Dunn,
p<0.05). �Significant difference when compared to Test baseline and Control baseline. ��Significant difference when compared to Test baseline.
§Significant difference when compared to Control baseline. ¶Significant difference when compared to Test baseline. #Significant difference when
compared to Control 30 days.
https://doi.org/10.1371/journal.pone.0238425.g003
PLOS ONE Bifidobacterium animalis HN019: A potential non-surgical treatment for periodontitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0238425 September 22, 2020 10 / 20
In vitro analysis of B. lactis HN019 antimicrobial activity
Means and standard deviations (mm) of the zones of inhibition obtained for the sensitivity of
different periodontopathogens to B. lactis HN019 are displayed in Fig 8. The probiotic strain
inhibited the growth of all periodontopathogens assessed.
Discussion
This double-blind randomized controlled trial assessed clinical and immunological effects of
B. lactis HN019 during non-surgical periodontal therapy in individuals with GCP. The find-
ings demonstrate that probiotic therapy improved plaque control, reduced BOMP, and
increased BD-3, TLR4 and CD-4 expressions in periodontal tissues. B. lactis HN019 also inhib-
ited the growth of periodontopathogens in in vitro tests and reduced the adhesion of P. gingi-
valis to BEC.
In the present study, the Test group had significantly lower PI than the Control group at 30
days. Some previous studies have demonstrated that Bifidobacterium spp. and Lactobacillus
spp. could quantitatively influence oral biofilm formation [19, 20]. Some probiotic strains may
form biofilm on hard and soft tissues, preventing the adhesion of pathogenic bacteria, and
they may also change the protein composition of the acquired salivary pellicle by binding and/
or degradation of salivary proteins [22].
Fig 4. Relative frequency values for CD-57 and CD-4 immunolabeling scores for test and control groups at healthy and
diseased sites at baseline and at 30 postoperative days, as well as within-group and between-group comparison results.
�Significant difference (Kruskal-Wallis, Dunn, p<0.05). �Significant difference when compared to Test baseline and Control
baseline. #Significant difference when compared to Control 30 days.
https://doi.org/10.1371/journal.pone.0238425.g004
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Bacterial coaggregation mechanisms are also likely to affect the quantity and quality of oral
biofilm. The probiotic strain used in the present study can perfectly adhere to subgingival bio-
films containing P. gingivalis, Actinomyces naeslundii, and F. nucleatum [33] and can coaggre-
gate with F. nucleatum [22]. The latter act as an actual “biological bridge” in oral biofilm
formation, as they adhere to virtually all oral bacteria [22]. The possible coaggregation of Bifi-
dobacterium with F. nucleatum may have reduced the number of binding sites for other bacte-
ria, affecting the quality and quantity of biofilm in patients from the Test group in the present
study. Moreover, B. lactis HN019 may have directly inhibited the growth of different periodon-
topathogens. Previous in vitro studies demonstrated that Bifidobacterium could inhibit the
growth of periodontopathogens [32, 33]. In the present study, B. lactis HN019 showed antimi-
crobial potential against P. gingivalis, P. intermedia, F. nucleatum, and A. actinomycetemcomi-
tans in in vitro sensitivity tests.
Probiotic therapy, even when administered for a short time period, seems to promote
remarkable resilience of the oral microbiome to risk factors for periodontitis, such as bacterial
plaque accumulation [34]. Notwithstanding a PI similar to that of the Control group at 90
days, the Test group had a lower BOMP, which indicates a possible delayed effect of probiotic
therapy on gingival inflammation. Lee et al. (2015) showed that Lactobacillus brevis lozenges
significantly delayed the onset of gingival inflammation in healthy individuals who refrained
from oral hygiene [35].
There are at least two ways to explain the lower gingival inflammation observed in patients
from the Test group in the present study. The first is related to the possible competition
between probiotic bacteria and periodontopathogens for binding sites. Mendi et al. (2016)
Fig 5. Photomicrographs showing BD-3 (A-H) and TLR4 (I-P) immunolabeling in gingival biopsies at baseline
(A, C, E, G, I, K, M, O) and 30 days (B, D, F, H, J, L, N, P) from healthy (A-D, I-L) and diseased (E-H, M-P) sites in
Test (A, B, E, F, I, J, M, N) and Control (C, D, G, H, K, L, O, P) groups. Arrows = BD-3 and TLR4-positive cells;
ep = Epithelial tissue; ct = Connective tissue. Scale = 25 μm. Counterstaining: Hematoxylin.
https://doi.org/10.1371/journal.pone.0238425.g005
PLOS ONE Bifidobacterium animalis HN019: A potential non-surgical treatment for periodontitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0238425 September 22, 2020 12 / 20
conducted an in vitro study and demonstrated that Lactobacillus rhamnosus can adhere to
mesenchymal stem cells in the gingiva, possibly protecting them from being colonized by P.
gingivalis [36]. In the in vitro assays performed in this study, B. lactis HN019 was able to adhere
to BEC and could reduce the adhesion of P. gingivalis to these cells. This is the first study to
assess the potential adhesion of B. lactis HN019 to BEC. The mean adhesion observed in the
present study was similar to the one found by Haukioja et al. (2006) for Lactobacillus rhamno-
sus GG in BEC [22]. However, it is important to emphasize that this study used only one vol-
unteer for collection of BEC. Considering that adhesion could vary in different individuals,
future studies should consider this. The second explanation could be related to a possible
interference of probiotic bacteria in the expression of markers involved in regulating the
Fig 6. Photomicrographs showing CD-57 (A-H) and CD-4 (I-P) immunolabeling in gingival biopsies (connective
tissue) at baseline (A, C, E, G, I, K, M, O) and 30 days (B, D, F, H, J, L, N, P) from healthy (A-D, I-L) and diseased
(E-H, M-P) sites in Test (A, B, E, F, I, J, M, N) and Control (C, D, G, H, K, L, O, P) groups. Arrows = CD-57 and
CD-4 positive cells. Scale = 25 μm. Counterstaining: Hematoxylin.
https://doi.org/10.1371/journal.pone.0238425.g006
Table 2. Adhesion of B. lactis HN019 and P. gingivalis to buccal epithelial cells. Mean ± standard deviation of the
bacteria counts.
Strains—Group Mean ± SD
Counts of B. lactis HN019 alone–Group B. lactis HN019 alone 16.57 ± 16.21
Counts of P. gingivalis alone–Group P. gingivalis alone 7.21 ± 3.88
Counts of B. lactis HN019 –Group B. lactis HN019 mixed with P. gingivalis 6.00 ± 12.66�
Counts of P. gingivalis–Group B. lactis HN019 mixed with P. gingivalis 4.63 ± 6.48�#
�Significant different when compared with Group B. lactis HN019 alone.
# Significant different when compared with Group P. gingivalis alone.
Binding to buccal epithelial cells = bacteria/cell–bacteria/cell in control (indigenous bacteria).
https://doi.org/10.1371/journal.pone.0238425.t002
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immunocompetence of the epithelial barrier. The gingival biopsies of diseased sites showed an
increase in BD-3 expression in Test group. A previous study showed that B. lactis HN019 also
increased BD-3 expression in periodontal tissues and reduced periodontal inflammation in
rats with experimental periodontitis [29]. BD are antimicrobial peptides that play an important
role in epithelial innate immunity and their differential expressions are associated with peri-
odontal diseases [37]. Among BDs, BD-3 is differentially induced by infectious or inflamma-
tory stimuli [38–40]. Some studies [41–43] demonstrated that inflamed periodontal sites have
lower BD-3 levels than do healthy sites. In the present study, Test group also exhibited higher
TLR4 expression than Control group. TLR4 is a recognition receptor that plays a crucial role
in the host’s innate response, as it helps identify lipopolysaccharides (LPS) of gram-negative
bacteria [44]. The administration of Lactobacillus casei CRL 431 in healthy mice increased the
number of TLR4-positive cells when compared to animals that were not treated with the probi-
otic. This finding, according to the authors, could indicate some improvement in physiological
surveillance mechanisms against pathogenic bacteria [45].
In this study, gingival biopsies of diseased sites presented greater expressions of CD-57 than
the ones of healthy sites. Natural killer (NK) cells, which are CD-57-positive, are lymphocytes
Fig 7. Photomicrographs showing buccal epithelial cells in adhesion assays using crystal violet and safranin. (A) P. gingivalis
alone attached in a buccal cell (original magnification x100). (B)–B. lactis HN019 alone attached in a buccal cell (original
magnification x100). (C)–Mixture of B. lactis HN019 with P. gingivalis attached in a buccal cell (original magnification x100). Red
arrows indicate P. gingivalis (Gram-negative bacteria with shorter rods or coccobacilli morphology). Blue arrows indicate
Bifidobacterium (Gram-positive bacteria with long bacilli morphology).
https://doi.org/10.1371/journal.pone.0238425.g007
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that differ from B and T cells in phenotype and function. The response of NK cells to patho-
gens and tumoral cells is almost immediate and occurs before the development of the adaptive
immune response [46]. Kopp (1988) observed an increase in NK cells in the gingiva of patients
with chronic periodontitis when compared with the gingiva of healthy subjects [47]. In the
present study, there were no significant differences in CD-57 immunolabeling pattern between
Test and Control groups, although there was less marginal gingival bleeding in Test group. In
fact, there are controversies in the literature regarding the relation between NK cells and the
severity of periodontal disease. While several studies demonstrated some correlation between
periodontal status and the number and phenotype of NK cells, others did not show any rela-
tion between them [47–51].
Besides innate immunity, cells of the adaptive immunity act in the pathogenesis of peri-
odontal diseases, specially CD4+ and CD8+ T cells (T-helper (Th) cells). In the present study,
diseased sites of patients of Test group presented greater expression of CD4+ cells than the
ones of Control group. In fact, probiotic therapy may influence the expression of CD4+ cells.
Probiotic administration increased CD4+ cells in the lamina propria of the small intestine of
mice that were exposed to an experimental model of stress induced by food and mobility
restriction [52]. Daily consumption of probiotics over a prolonged period of time may improve
CD4+ count in people living with HIV [53]. It is important to emphasize that, in the pathogen-
esis of periodontal diseases, CD4+ cells function over other cell types can be dual depending
on the cytokines produced [54]. In the present study, it is likely that CD4+ cells of Test group
presented a phenotype related to the production of anti-inflammatory cytokines. Invernici
et al. (2018) demonstrated that patients treated with B. lactis HN019 presented lower proin-
flammatory cytokine levels in gingival crevicular fluid than the patients not treated [30].
IgA is an important defense factor found in the saliva and it influences the oral microbiota,
interfering with bacterial adhesion and metabolism [55]. The probiotic therapy used in the
Fig 8. Growth inhibition of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, and Fusobacterium
nucleatum by Bifidobacterium animalis subs. Lactis HN019 (agar diffusion method). (A) Clear areas around the wells indicate zones of inhibition.
(B) Means and standard deviations of the zone of inhibition observed in sensitivity of different periodontopathogens to B. lactis HN019.
https://doi.org/10.1371/journal.pone.0238425.g008
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present study did not change IgA levels in the saliva. Studies on immunoregulatory effects of
probiotic bacteria involving IgA have shown contradictory and inconclusive outcomes [56].
While several studies showed that probiotic bacteria of the genus Lactobacillus [57–61] did not
increase IgA levels, other studies revealed high IgA concentrations [62–66] in patients treated
with probiotic strains of the genera Bifidobacterium, Lactobacillus, or Enterococcus. There
could be many reasons for the conflicting findings, such as heterogeneous research models,
type of saliva, and analytical methodology [56]. Furthermore, the assessed saliva might not
fully indicate the composition of salivary glands.
The short period of assessment is a limitation of this study. A long-term follow-up of the
patients would be important to evaluate whether the additional effects obtained with probiotic
therapy during non-surgical periodontal therapy will be sustained over time. It is also impor-
tant that future investigations evaluate new methods of administration of B. lactis HN019 and
other therapeutic regimens for the treatment of periodontitis patients. The effect of B. lactis
HN019 on patients with gingivitis should also be investigated as well.
Conclusions
In conclusion, the immunological and antimicrobial properties of B. lactis HN019 make it a
potential probiotic to be used in non-surgical periodontal therapy of patients with GCP.
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